Literature DB >> 14997306

[Patients in circulatory shock in emergency and intensive care units].

A N Laggner1.   

Abstract

Patients in circulatory shock are being treated in emergency as well as in intensive care units. Despite different resources in personnel and technical equipment in both areas, patient management has to follow standardized protocols. Diagnosis of shock has to be based upon objective parameters (lactate, pH, standard bicarbonate, arterial blood pressure, central venous pressure, cardiac output). Aim of shock treatment is restoration of adequate tissue perfusion with the use of fluid and red blood cell replacement, vasoconstrictors, inotropics, substances improving microcirculation, and mechanical circulatory support. Target values are: mean arterial blood pressure >80 mmHg, central venous pressure >6 mmHg, hemoglobin >8.0 g/dl, cardiac index >3.5 l/min/m(2). New concepts for optimization of hemodynamics and hematocrit, cortisone, intraaortic balloon counterpulsation, mechanical ventilation with low tidal volumes, and intensive insulin therapy are discussed. However, as shock reversal is dependent on its reason, clarification and treatment of the shock causing event has to be performed with highest priority.

Entities:  

Mesh:

Year:  2004        PMID: 14997306     DOI: 10.1007/s00108-003-1140-0

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  19 in total

Review 1.  Is blood transfusion good for the heart?

Authors:  S D Surgenor; M J Hampers; H L Corwin
Journal:  Crit Care Med       Date:  2001-02       Impact factor: 7.598

2.  Meta-analysis of acute lung injury and acute respiratory distress syndrome trials testing low tidal volumes.

Authors:  Peter Q Eichacker; Eric P Gerstenberger; Steven M Banks; Xizhong Cui; Charles Natanson
Journal:  Am J Respir Crit Care Med       Date:  2002-08-28       Impact factor: 21.405

3.  Impact of randomized trial results on acute lung injury ventilator therapy in teaching hospitals.

Authors:  Craig R Weinert; Cynthia R Gross; William A Marinelli
Journal:  Am J Respir Crit Care Med       Date:  2003-02-05       Impact factor: 21.405

4.  Pro/Con debate of activated protein C in severe sepsis.

Authors:  J C A Joore; H J van Leeuwen; J Meulenbelt; T J M Tobé; J W Fijen; J W Figen
Journal:  Crit Care Med       Date:  2003-08       Impact factor: 7.598

5.  Is a low transfusion threshold safe in critically ill patients with cardiovascular diseases?

Authors:  P C Hébert; E Yetisir; C Martin; M A Blajchman; G Wells; J Marshall; M Tweeddale; G Pagliarello; I Schweitzer
Journal:  Crit Care Med       Date:  2001-02       Impact factor: 7.598

6.  Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome.

Authors:  Roy G Brower; Michael A Matthay; Alan Morris; David Schoenfeld; B Taylor Thompson; Arthur Wheeler
Journal:  N Engl J Med       Date:  2000-05-04       Impact factor: 91.245

7.  Immunologic and hemodynamic effects of "low-dose" hydrocortisone in septic shock: a double-blind, randomized, placebo-controlled, crossover study.

Authors:  Didier Keh; Thomas Boehnke; Steffen Weber-Cartens; Christina Schulz; Olaf Ahlers; Sven Bercker; Hans-Dieter Volk; Wolf-Dietrich Doecke; Konrad J Falke; Herwig Gerlach
Journal:  Am J Respir Crit Care Med       Date:  2002-11-08       Impact factor: 21.405

8.  Elevation of systemic oxygen delivery in the treatment of critically ill patients.

Authors:  M A Hayes; A C Timmins; E H Yau; M Palazzo; C J Hinds; D Watson
Journal:  N Engl J Med       Date:  1994-06-16       Impact factor: 91.245

9.  Adrenal insufficiency during septic shock.

Authors:  Paul E Marik; Gary P Zaloga
Journal:  Crit Care Med       Date:  2003-01       Impact factor: 7.598

10.  Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock.

Authors:  Djillali Annane; Véronique Sébille; Claire Charpentier; Pierre-Edouard Bollaert; Bruno François; Jean-Michel Korach; Gilles Capellier; Yves Cohen; Elie Azoulay; Gilles Troché; Philippe Chaumet-Riffaud; Philippe Chaumet-Riffaut; Eric Bellissant
Journal:  JAMA       Date:  2002-08-21       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.